+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-Rheumatics Market by Drug Class (Corticosteroids, Disease Modifying Anti-rheumatics Drugs, Nonsteroidal Anti-inflammatory Drugs), Route Of Administration (Injectable, Oral, Topical), Type, Disease Type, Distribution Channel - Global Forecast 2025-2030- Product Image
Anti-Rheumatics Market by Drug Class (Corticosteroids, Disease Modifying Anti-rheumatics Drugs, Nonsteroidal Anti-inflammatory Drugs), Route Of Administration (Injectable, Oral, Topical), Type, Disease Type, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Anti-Rheumatics Market by Drug Class (Corticosteroids, Disease Modifying Anti-rheumatics Drugs, Nonsteroidal Anti-inflammatory Drugs), Route Of Administration (Injectable, Oral, Topical), Type, Disease Type, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6014950
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The anti-rheumatics market is experiencing rapid transformation as innovation, policy changes, and evolving care delivery models redefine the strategic priorities for industry leaders and stakeholders. This dynamic environment requires decision-makers to adopt agile and informed approaches to optimize outcomes and competitive positioning.

Market Snapshot: Anti-Rheumatics Market Growth and Opportunity

The Anti-Rheumatics Market grew from USD 96.56 billion in 2024 to USD 101.95 billion in 2025. It is expected to continue expanding at a CAGR of 5.71%, reaching USD 134.77 billion by 2030.

Scope & Segmentation

  • Drug Classes: Corticosteroids, Disease Modifying Anti-rheumatics Drugs (including Biologic DMARDs, Conventional DMARDs, Targeted Synthetic DMARDs), Nonsteroidal Anti-inflammatory Drugs, Uric Acid Drugs.
  • Biologic DMARD Subtypes: B-cell Inhibitors, Interleukin Inhibitors, T-cell Co-stimulation Modulators, Tumor Necrosis Factor (TNF) Inhibitors.
  • Route of Administration: Injectable, Oral, Topical.
  • Type: Over-the-Counter Drugs, Prescription-Based Drugs.
  • Disease Categories: Ankylosing Spondylitis, Bursitis, Gout, Juvenile Idiopathic Arthritis, Osteoarthritis, Osteoporosis, Polymyalgia Rheumatica, Psoriatic Arthritis, Rheumatoid Arthritis, Sjögren's Syndrome, Systemic Lupus Erythematosus, Systemic Sclerosis/Scleroderma, Tendinitis.
  • Distribution Channels: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies.
  • Regions: Americas (including United States, Canada, Mexico, Brazil, Argentina); Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland); Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Key Companies: AbbVie Inc., Alvotech, Amgen Inc., ANI Pharmaceuticals, Inc., AstraZeneca PLC, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, C. H. Boehringer Sohn AG & Co. KG, DeepCure, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Fresenius Kabi AG, Galapagos NV, Gilead Sciences, Inc., GlaxoSmithKline PLC, ILTOO Pharma SAS, Johnson & Johnson Services Inc., medac GmbH, Merck & Co., Inc., Novartis AG, Otter Pharmaceuticals, LLC by Assertio Holdings, Inc., Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., Vertex Pharmaceuticals Incorporated.

Key Takeaways for Senior Decision-Makers

  • The anti-rheumatics market is evolving rapidly due to technological advancements, including the mainstream adoption of biologics and targeted synthetic treatments.
  • Digital health technologies, such as telemonitoring and AI-based diagnostic tools, are improving early detection and patient adherence, leading to better care delivery and operational efficiency.
  • Regulatory environments are adapting, with agencies shifting towards more flexible approval processes and encouraging real-world evidence for quicker market access while maintaining safety standards.
  • Companies are focusing on value-based contracting, which rewards clinical outcomes instead of sales volume, reshaping commercial strategies.
  • Emerging partnerships between major pharmaceutical firms and biotech leaders are driving development pipelines, while market entrants challenge existing models with innovations in drug delivery and patient targeting.
  • Regional challenges and opportunities require distinct strategic approaches, given disparate reimbursement frameworks and varying levels of generic competition across the Americas, EMEA, and Asia-Pacific.

Tariff Impact: Navigating Cost and Access Challenges

Recent changes to United States tariff structures have introduced new complexities for anti-rheumatic drug supply chains. Higher import duties on essential pharmaceutical ingredients are prompting manufacturers to localize production and seek alternative sourcing arrangements. This shift has heightened price sensitivity among stakeholders, underscoring the need for adaptive pricing and robust risk management to safeguard access to critical therapies in the evolving trade environment.

Methodology & Data Sources

This report is based on a blend of primary interviews with leading industry stakeholders—rheumatologists, pharmacists, payers, and executives—and comprehensive analysis of peer-reviewed literature, clinical trial data, regulatory filings, and company disclosures. Insights were further validated by an expert review panel and strengthened through systematic data triangulation.

Why This Report Matters for Industry Leaders

  • Enables strategic alignment by providing in-depth understanding of market segments, geographical dynamics, and innovation trends, critical for portfolio optimization and investment planning.
  • Arms senior executives with actionable recommendations for navigating evolving regulatory pathways, supply chain risks, and payer expectations in value-driven care models.
  • Supports decision-making through robust, validated insights into the competitive landscape and high-impact collaboration opportunities within the anti-rheumatic therapies sector.

Conclusion

The anti-rheumatics market is defined by continuous innovation, regulatory evolution, and the need for tailored engagement across diverse regions. Informed, strategic actions will be essential for maintaining leadership and creating value in this competitive landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of personalized biologic therapies based on patient genetic markers for rheumatoid arthritis treatment optimization
5.2. Expansion of biosimilar infliximab and etanercept formulations improving affordability in emerging markets
5.3. Adoption of telemedicine and remote monitoring platforms for early detection of rheumatoid arthritis flares
5.4. Development of orally bioavailable JAK inhibitors targeting multiple inflammatory pathways in rheumatoid arthritis
5.5. Clinical trials evaluating combination use of IL-17 and TNF inhibitors for refractory psoriatic arthritis management
5.6. Emerging real-world evidence demonstrating long-term safety profiles of next-generation anti-rheumatic agents
5.7. Implementation of patient-centric digital health tools to improve adherence to anti-rheumatoid treatment regimens
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Anti-Rheumatics Market, by Drug Class
8.1. Introduction
8.2. Corticosteroids
8.3. Disease Modifying Anti-rheumatics Drugs
8.3.1. Biologic DMARDs
8.3.1.1. B-cell Inhibitors
8.3.1.2. Interleukin Inhibitors
8.3.1.3. T-cell Co-stimulation Modulators
8.3.1.4. Tumor Necrosis Factor (TNF) Inhibitors
8.3.2. Conventional DMARDs
8.3.3. Targeted Synthetic DMARDs
8.4. Nonsteroidal Anti-inflammatory Drugs
8.5. Uric Acid Drugs
9. Anti-Rheumatics Market, by Route Of Administration
9.1. Introduction
9.2. Injectable
9.3. Oral
9.4. Topical
10. Anti-Rheumatics Market, by Type
10.1. Introduction
10.2. Over-the-Counter Drugs
10.3. Prescription-Based Drugs
11. Anti-Rheumatics Market, by Disease Type
11.1. Introduction
11.2. Ankylosing Spondylitis
11.3. Bursitis
11.4. Gout
11.5. Juvenile Idiopathic Arthritis
11.6. Osteoarthritis
11.7. Osteoporosis
11.8. Polymyalgia Rheumatica
11.9. Psoriatic Arthritis
11.10. Rheumatoid Arthritis
11.11. Sjögren's Syndrome
11.12. Systemic Lupus Erythematosus
11.13. Systemic Sclerosis/Scleroderma
11.14. Tendinitis
12. Anti-Rheumatics Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Americas Anti-Rheumatics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Anti-Rheumatics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Anti-Rheumatics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AbbVie Inc.
16.3.2. Alvotech
16.3.3. Amgen Inc.
16.3.4. ANI Pharmaceuticals, Inc.
16.3.5. AstraZeneca PLC
16.3.6. Bayer AG
16.3.7. Biogen Inc.
16.3.8. Bristol-Myers Squibb Company
16.3.9. C. H. Boehringer Sohn AG & Co. KG
16.3.10. DeepCure
16.3.11. Eisai Co., Ltd.
16.3.12. Eli Lilly and Company
16.3.13. F. Hoffmann-La Roche Ltd.
16.3.14. Fresenius Kabi AG
16.3.15. Galapagos NV
16.3.16. Gilead Sciences, Inc.
16.3.17. GlaxoSmithKline PLC
16.3.18. ILTOO Pharma SAS
16.3.19. Johnson & Johnson Services Inc.
16.3.20. medac GmbH
16.3.21. Merck & Co., Inc.
16.3.22. Novartis AG
16.3.23. Otter Pharmaceuticals, LLC by Assertio Holdings, Inc.
16.3.24. Pfizer, Inc.
16.3.25. Regeneron Pharmaceuticals, Inc.
16.3.26. Sanofi SA
16.3.27. Takeda Pharmaceutical Company Limited
16.3.28. Teva Pharmaceutical Industries Ltd.
16.3.29. UCB S.A.
16.3.30. Vertex Pharmaceuticals Incorporated
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ANTI-RHEUMATICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ANTI-RHEUMATICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ANTI-RHEUMATICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ANTI-RHEUMATICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. ANTI-RHEUMATICS MARKET: RESEARCHAI
FIGURE 26. ANTI-RHEUMATICS MARKET: RESEARCHSTATISTICS
FIGURE 27. ANTI-RHEUMATICS MARKET: RESEARCHCONTACTS
FIGURE 28. ANTI-RHEUMATICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ANTI-RHEUMATICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTI-RHEUMATICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ANTI-RHEUMATICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY B-CELL INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY B-CELL INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY T-CELL CO-STIMULATION MODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY T-CELL CO-STIMULATION MODULATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TUMOR NECROSIS FACTOR (TNF) INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TUMOR NECROSIS FACTOR (TNF) INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TARGETED SYNTHETIC DMARDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TARGETED SYNTHETIC DMARDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY URIC ACID DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY URIC ACID DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BURSITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BURSITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY GOUT, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY GOUT, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY JUVENILE IDIOPATHIC ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY JUVENILE IDIOPATHIC ARTHRITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOPOROSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOPOROSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY POLYMYALGIA RHEUMATICA, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY POLYMYALGIA RHEUMATICA, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SJÖGREN'S SYNDROME, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SJÖGREN'S SYNDROME, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC SCLEROSIS/SCLERODERMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC SCLEROSIS/SCLERODERMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TENDINITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TENDINITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 119. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 120. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 121. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2024 (USD MILLION)
TABLE 122. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2025-2030 (USD MILLION)
TABLE 123. CANADA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2024 (USD MILLION)
TABLE 124. CANADA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2025-2030 (USD MILLION)
TABLE 125. CANADA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 126. CANADA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 127. CANADA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 128. CANADA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 129. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 130. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 131. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 134. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 135. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2024 (USD MILLION)
TABLE 136. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2025-2030 (USD MILLION)
TABLE 137. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2024 (USD MILLION)
TABLE 138. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2025-2030 (USD MILLION)
TABLE 139. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 140. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 141. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 142. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 143. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 144. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 145. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 202. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 206. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 207. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2024 (USD MILLION)
TABLE 208. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2025-2030 (USD MILLION)
TABLE 209. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2024 (USD MILLION)
TABLE 210. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2025-2030 (USD MILLION)
TABLE 211. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 214. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 215. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 216. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 217. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 220. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 221. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2024 (USD MILLION)
TABLE 222. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2025-2030 (USD MILLION)
TABLE 223. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2024 (USD MILLION)
TABLE 224. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2025-2030 (USD MILLION)
TABLE 225. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 226. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 227. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 228. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 229. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 230. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 231. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 248. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 249. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2024 (USD MILLION)
TABLE 250. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2025-2030 (USD MILLION)
TABLE 251. ITALY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2024 (USD MILLION)
TABLE 252. ITALY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2025-2030 (USD MILLION)
TABLE 253. ITALY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 254. ITALY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 255. ITALY ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 256. ITALY ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 257. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 258. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 259. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 260. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 261. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 262. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 263. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2024 (USD MILLION)
TABLE 264. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2025-2030 (USD MILLION)
TABLE 265. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2024 (USD MILLION)
TABLE 266. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2025-2030 (USD MILLION)
TABLE 267. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 268. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 269. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 270. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 271. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 272. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 273. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 274. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2024 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2025-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2024 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 289. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 290. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 291. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2024 (USD MILLION)
TABLE 292. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2025-2030 (USD MILLION)
TABLE 293. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2024 (USD MILLION)
TABLE 294. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2025-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 296. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 298. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 303. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 304. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 305. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2024 (USD MILLION)
TABLE 306. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2025-2030 (USD MILLION)
TABLE 307. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2024 (USD MILLION)
TABLE 308. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2025-2030 (USD MILLION)
TABLE 309. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 310. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 312. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 314. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 316. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 317. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 318. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 319. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2024 (USD MILLION)
TABLE 320. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2025-2030 (USD MILLION)
TABLE 321. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2024 (USD MILLION)
TABLE 322. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2025-2030 (USD MILLION)
TABLE 323. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 324. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 325. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 326. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 327. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 328. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 329. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 330. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 331. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 332. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 333. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2024 (USD MILLION)
TABLE 334. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYI

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Anti-Rheumatics market report include:
  • AbbVie Inc.
  • Alvotech
  • Amgen Inc.
  • ANI Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • C. H. Boehringer Sohn AG & Co. KG
  • DeepCure
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Galapagos NV
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • ILTOO Pharma SAS
  • Johnson & Johnson Services Inc.
  • medac GmbH
  • Merck & Co., Inc.
  • Novartis AG
  • Otter Pharmaceuticals, LLC by Assertio Holdings, Inc.
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.
  • Vertex Pharmaceuticals Incorporated

Table Information

Report AttributeDetails
No. of Pages192
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 101.95 Billion
Forecasted Market Value ( USD ) by 2030 $ 134.77 Billion
Compound Annual Growth Rate5.7%
Regions CoveredGlobal
No. of Companies Mentioned31

Related Topics

Related Reports

Anti-Inflammatory Therapeutics: Market Share, and Growth Analysis by Product Type (Non-steroidal Anti-inflammatory Drugs, Corticosteroids, Disease Modifying Anti-rheumatic Drugs), Application, End User, Technology - Product Image

Anti-Inflammatory Therapeutics: Market Share, and Growth Analysis by Product Type (Non-steroidal Anti-inflammatory Drugs, Corticosteroids, Disease Modifying Anti-rheumatic Drugs), Application, End User, Technology

  • Report
  • 150 Pages
  • Global
From
Anti-Inflammatory Drugs Global Market Report 2025 - Product Image

Anti-Inflammatory Drugs Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Rheumatology Therapeutics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F - Product Image

Rheumatology Therapeutics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Anti-Inflammatory Therapeutics Market Report 2025 - Product Image

Anti-Inflammatory Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Systemic Lupus Erythematosus Market by Treatment Type (Biologics, Conventional Synthetic Dmards, Corticosteroids), Product Type (Biosimilar, Innovator), Distribution Channel, End User, Route Of Administration - Global Forecast 2025-2030 - Product Image

Systemic Lupus Erythematosus Market by Treatment Type (Biologics, Conventional Synthetic Dmards, Corticosteroids), Product Type (Biosimilar, Innovator), Distribution Channel, End User, Route Of Administration - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.